Xsolla Expands Payments in the Americas to Boost Conversions With Pay by Bank, Affirm, and Recurring Billing via Mercado Pago
14.8.2025 21:00:00 CEST | Business Wire | Press Release
Xsolla, a global commerce company helping developers launch, grow and monetize their games, announces today a major expansion of its localized payments offering across North and South America today. With new support for Pay by Bank and Affirm in the United States, Affirm in Canada, and recurring billing via Mercado Pago in Brazil, developers and publishers using Xsolla Pay Station can now unlock new revenue streams, reduce friction, and better connect with players through regionally trusted payment methods.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250814368955/en/
(Graphic: Xsolla)
The Americas remain one of the largest and most diverse gaming regions, with a combined market value of approximately USD 100 billion. However, while opportunities are vast, consumer expectations regarding payments vary dramatically by country. Players in the U.S. increasingly seek fast, secure alternatives to credit cards; Canadian gamers are embracing flexible payment options; and in Brazil, a major economy, recurring billing through trusted platforms like Mercado Pago is essential for long-term retention.
To meet these regional needs, Xsolla Pay Station now supports:
-
Pay by Bank in the U.S. – Faster, secure, bank-direct payments are rapidly gaining traction among players and retailers.
-
Affirm in the U.S. (live) and Canada – A flexible Buy Now, Pay Later option that increases accessibility and basket size.
- Mercado Pago in Brazil (enhanced) – Now supporting recurring billing to enable live service models and subscription-based monetization.
Key benefits of the Payments in the Americas expansion include:
- Localized Payment Solutions: Offer trusted regional payment methods, including Pay by Bank, Affirm, and Mercado Pago, ensuring players can pay in their preferred manner in every market. Reflects the growing consumer shift toward convenient, secure, and flexible payment methods.
- Frictionless Checkout Experiences: Mobile-first, secure payment flows help reduce abandonment and improve conversion rates.
- Wider Reach Across North & South America: Localized support in the U.S., Canada, and Brazil opens access to millions of players, backed by the adoption of Pay by Bank (35M+ U.S. users engaging with open banking), Affirm (22M+ U.S. shoppers as of 2024), and Mercado Pago (64M monthly active users in Brazil, integrated across 145,000+ live sites), reflecting the growing demand for convenient, secure, and flexible payment experiences.
- Flexible Monetization Models: To fit your revenue strategy, offer one-time payments, Buy Now Pay Later (BNPL) options, and subscriptions.
- Increased Player Trust and Loyalty: Familiar payment methods foster confidence and encourage players to return.
“We’re making it easier for developers to reach players in North and South America with payment experiences that feel native to each market,” said Chris Hewish, President at Xsolla. “By enabling Pay by Bank, Affirm, and recurring billing with Mercado Pago, we’re helping our partners connect with more players, increase conversions, and offer real flexibility in how they monetize across the Americas.”
To learn more or enable these regional payment methods for your game, get started: https://publisher.xsolla.com/
For a complete list of enhancements and developer tools, visit: xsolla.pro/rws25paymentsinamerica
About Xsolla
Xsolla is a global commerce company with robust tools and services to help developers solve the inherent challenges of the video game industry. From indie to AAA, companies partner with Xsolla to help them fund, distribute, market, and monetize their games. Grounded in the belief in the future of video games, Xsolla is resolute in the mission to bring opportunities together, and continually make new resources available to creators. Headquartered and incorporated in Los Angeles, California, Xsolla operates as the merchant of record and has helped over 1,500+ game developers to reach more players and grow their businesses around the world. With more paths to profits and ways to win, developers have all the things needed to enjoy the game.
For more information, visit xsolla.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250814368955/en/
Contacts
Media Contact
Derrick Stembridge
Vice President of Global Public Relations, Xsolla
d.stembridge@xsolla.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom